Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy

Antheia 在 C 轮融资中筹集 5600 万美元，以推动全球商业化战略

New funding will support the company's rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform

新资金将支持公司的快速增长轨迹，并通过其先进的生物制造平台努力改变制药供应链。

MENLO PARK, Calif., June 3, 2025-- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has raised $56 million in Series C financing. The new financing will be used to expand commercialization of Antheia's first product, thebaine, and launch additional products from the company's pipeline of 70+ biosynthetic pharmaceutical ingredients, which spans seven therapeutic areas and prioritizes essential medicines in or at risk of shortage.

门洛帕克，加利福尼亚州，2025年6月3日——Antheia是一家正在变革基本药物供应链的制药原料制造商，今天宣布已完成5600万美元的C轮融资。这笔新资金将用于扩大Antheia首款产品蒂巴因的商业化规模，并推出公司70多种生物合成药物成分管线中的其他产品，这些产品涵盖七个治疗领域，优先考虑供应短缺或面临短缺风险的基本药物。

Additionally, the funding will allow Antheia to unlock its U.S. manufacturing operations to meet domestic demand and begin new strategic innovation programs in Singapore, while expanding into the broader Asia region..

此外，这笔资金将使Antheia能够启动其美国制造业务以满足国内需求，并在新加坡开始新的战略创新计划，同时扩展到更广泛的亚洲地区。

'Our industry-first biosynthetic product offerings are disrupting the market by addressing major supply chain issues and are quickly cementing Antheia's position as a leading industry innovator,' said Dr. Christina Smolke, CEO and co-founder of Antheia. 'In collaboration with our investors, customers, and manufacturing partners, we are enabling widespread access to critical medicines with our world-leading biosynthesis technology.

“我们行业首创的生物合成产品正在通过解决主要的供应链问题来颠覆市场，并迅速巩固Antheia作为行业领先创新者的地位，”Antheia首席执行官兼联合创始人克里斯蒂娜·斯莫尔克博士表示。“通过与我们的投资者、客户和制造合作伙伴合作，我们正利用世界领先的生物合成技术，使关键药物得到广泛获取。”

We are immensely grateful to these partners that share our vision for the next generation of pharma, and we look forward to achieving more industry-first milestones with today's financing.'.

我们非常感谢这些与我们共享下一代制药愿景的合作伙伴，我们期待通过今天的融资实现更多行业首创的里程碑。

Drug shortages remain a persistent problem plaguing nations worldwide and are exacerbated by supply chain disruptions, climate crises, and shifting geopolitics. Antheia's biomanufacturing platform is ushering in the next era of efficient, agile, and distributed pharmaceutical manufacturing that can be implemented when and where needed to meet the demands of 21st century healthcare systems..

药品短缺仍然是困扰世界各国的持续性问题，并因供应链中断、气候危机和地缘政治变化而加剧。Antheia的生物制造平台正在引领高效、灵活和分布式制药生产的新时代，该平台可以根据21世纪医疗系统的需求，在需要的时间和地点实施。

The Series C financing was led by Global Health Investment Corporation (GHIC), a U.S.-based investment firm with an established history of supporting innovation in global health and health security and EDBI, operating under SG Growth Capital, the investment platform of the Singapore Economic Development Board (EDB) and Enterprise Singapore.

本轮融资由环球健康投资公司 (GHIC) 和新加坡经济发展局 (EDB) 旗下投资平台新加坡成长资本 (SG Growth Capital) 运营的 EDBI 领投。GHIC 是一家总部位于美国的投资公司，拥有支持全球健康和健康安全领域创新的悠久历史。

Additional new investors in this round include ATHOS KG and Federov, with participation from existing investors, including Viking Global Investors, Sherpalo Ventures, S-Cubed Capital, In-Q-Tel (IQT), and Civilization Ventures..

本轮融资的新投资者还包括ATHOS KG和Federov，现有投资者也参与其中，包括Viking Global Investors、Sherpalo Ventures、S-Cubed Capital、In-Q-Tel（IQT）和Civilization Ventures。

'Global pharmaceutical supply chains are complex and increasingly vulnerable to critical drug shortages – an urgent health security challenge,' said Joseph Lee, Principal at GHIC. 'Antheia's biosynthesis platform offers a transformative and elegant solution, enabling more efficient, scalable, and reliable production of KSMs and APIs.

“全球制药供应链复杂，越来越容易出现关键药物短缺的情况，这是一个紧迫的卫生安全挑战，”GHIC负责人约瑟夫·李表示。“Antheia的生物合成平台提供了一个变革性且优雅的解决方案，能够更高效、可扩展和可靠地生产关键起始物料（KSM）和活性药物成分（API）。”

We are excited to support Antheia's next phase of growth and to partner in building a more resilient future for global biomanufacturing.'.

我们很高兴能够支持Antheia的下一阶段增长，并合作为全球生物制造构建一个更具韧性的未来。

'Antheia's pioneering biosynthesis platform transforms essential medicine supply chains by addressing critical bottlenecks. As Singapore strengthens its position as Asia's biotech hub, EDBI is proud to partner with Antheia to advance bio-based innovation. We see significant opportunities for Antheia to expand its biomanufacturing capabilities and applications through collaborations with Singapore's vibrant scientific ecosystem – including A*STAR, Singapore's lead public sector R&D agency – creating valuable synergies for future growth across Asia,' said Paul Ng, Chief Executive Officer of EDBI..

“Antheia 先进的生物合成平台通过解决关键瓶颈问题，彻底改变了重要药物的供应链。随着新加坡巩固其作为亚洲生物技术中心的地位，EDBI 很荣幸与 Antheia 合作推动基于生物的创新。我们看到 Antheia 通过与新加坡充满活力的科学生态系统（包括新加坡主要的公共部门研发机构 A*STAR）合作，在扩展其生物制造能力和应用方面拥有巨大的机会，为亚洲未来的增长创造宝贵的协同效应，”EDBI 首席执行官 Paul Ng 表示。

Today's news comes on the heels of several major milestones, including Antheia's first commercial delivery of thebaine – the key ingredient used to produce Narcan – and two U.S. government project agreements valued up to a combined $23 million to onshore pharmaceutical supply chains. Antheia's strong commercial momentum and the broader industry response underscore the company's vital role in modernizing global pharmaceutical supply chains and realizing biomanufacturing's potential to solve the world's most pressing problems..

今天的新闻紧随几个重大里程碑而来，包括Antheia首次商业交付用于生产Narcan的关键成分蒂巴因，以及两份美国政府项目协议，总价值高达2300万美元，旨在本土化制药供应链。Antheia强劲的商业势头以及整个行业的积极响应，凸显了该公司在现代化全球制药供应链和实现生物制造潜力以解决世界最紧迫问题方面的重要作用。

About Antheia

关于Antheia

Antheia is the next-generation pharmaceutical ingredient producer with a mission to end drug shortages. Using advanced biosynthesis and fermentation technology, Antheia's biomanufacturing platform enables rapid, efficient, agile, and on-demand production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) that are critical to public health.

Antheia是一家下一代制药原料生产商，致力于终结药品短缺问题。通过先进的生物合成和发酵技术，Antheia的生物制造平台能够快速、高效、灵活地按需生产对公共健康至关重要的关键起始物料（KSM）和活性药物成分（API）。

This highly flexible approach supports the needs of a growing society and improves global access to essential medicines. Founded in 2015, Antheia has grown into a commercial stage company with its first product to market, an active customer pipeline, and near-term product launches. For more information on how Antheia is transforming pharmaceutical supply chains, visit www.antheia.bio..

这种高度灵活的方法支持了不断增长的社会需求，并改善了全球对基本药物的获取。Antheia 成立于2015年，现已发展为一家进入商业化阶段的公司，其首款产品已上市，拥有活跃的客户管道和近期即将推出的产品。如需更多关于 Antheia 如何变革医药供应链的信息，请访问 www.antheia.bio。

Contact:

联系人：

MEDIA CONTACT:

媒体联系人：

Mission North for Antheia

北向任务：安瑟亚

antheia@missionnorth.com

安忒亚@任务北.com